John Coleman, PhD
Co-founder and Chief Executive Officer
John has a wide-ranging scientific and business background. His PhD research on anticancer compounds produced the drug candidate HTI-286 that was licensed to Wyeth, and it progressed to Phase II clinical trials. He’s also an inventor on four patents and the author of thirteen publications.
Prior to founding Anandia Labs with Jonathan Page in 2013, John was the Department Head of the Centre for Drug Research and Development’s (CDRD) Project Search and Evaluation Division (2007-2015). He was responsible for establishing and managing partnerships with academic institutions and identifying projects with therapeutic and commercial potential.
Before joining CDRD, he held various positions at Inflazyme Pharmaceuticals Ltd. (2000-2007), a Vancouver-based biotechnology company specializing in the development of treatments for respiratory and inflammatory diseases. Prior to Inflazyme, John led the natural products group at Ocean Nutrition Canada (1999-2000) after having completed a postdoctoral fellowship in the Marine Natural Products Chemistry group at the National Research Council in Halifax, Nova Scotia (1998-1999).
John holds a BSc. (Honours) from Bishop’s University (1992) and a PhD from the University of British Columbia (1997).